Press Release: Availability of the Q4 2022 Memorandum for modelling purposes
04 Gennaio 2023 - 7:30AM
Availability of the Q4 Memorandum for modelling purposes
Paris, France – January
4, 2023
- Sanofi announced today that its Q4 2022 Memorandum for modelling
purposes is available on the "Investors" page of the company's
website:
https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q4-results-2022
As for each quarter, Sanofi prepared this
document to assist in the financial modelling of the Group's
quarterly results. This document includes a reminder on various
non-comparable items and exclusivity losses as well as the foreign
currency impact and share count. Sanofi's fourth-quarter 2022
results will be published on February 3, 2023.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25 |
sandrine.guendoul@sanofi.com Sally Bain | + 1
617 834 6026 | sally.bain@sanofi.com Nicolas
Obrist | + 33 06 77 21 27 55 |
nicolas.obrist@sanofi.com Victor Rouault | +
33 06 70 93 71 40 | victor.rouault@sanofi.com
Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39 |
eva.schaefer-jansen@sanofi.com Arnaud
Delépine | + 33 06 73 69 36 93 |
arnaud.delepine@sanofi.com Corentine
Driancourt | + 33 06 40 56 92 |
corentine.driancourt@sanofi.com Felix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.com Priya Nanduri | + 1
617 764 6418 | priya.nanduri@sanofi.com
Nathalie Pham | + 33 07 85 93
30 17 | nathalie.pham@sanofi.com
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest rates,
volatile economic and market conditions, cost containment
initiatives and subsequent changes thereto, and the impact that
COVID-19 will have on us, our customers, suppliers, vendors, and
other business partners, and the financial condition of any one of
them, as well as on our employees and on the global economy as a
whole. Any material effect of COVID-19 on any of the foregoing
could also adversely impact us. This situation is changing rapidly
and additional impacts may arise of which we are not currently
aware and may exacerbate other previously identified risks. The
risks and uncertainties also include the uncertainties discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2021. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Ott 2023 a Ott 2024